Patent
Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.
1. An isolated polypeptide having at least 95% identity to SEQ ID NO: 2, wherein said isolated polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual.
2. An isolated polypeptide comprising the amino acid sequence consisting of SEQ ID NO:2.
3. An isolated polypeptide comprising the amino acid sequence consisting of amino acids 2 to 1039 of SEQ ID NO:2.
4. An isolated polypeptide comprising the amino acid sequence consisting of amino acids 21 to 1039 of SEQ ID NO:2.
5. A vaccine composition comprising a polypeptide having at least 95% identity to SEQ ID NO: 2, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual, and a pharmaceutically acceptable adjuvant.
6. A vaccine composition comprising a polypeptide having at least 95% sequence identity with a polypeptide comprising the amino acid sequence consisting of amino acids 2 to 1039 of SEQ ID NO:2, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual, and a pharmaceutically acceptable adjuvant.
7. A vaccine composition comprising a polypeptide having at least 95% sequence identity with a polypeptide comprising the amino acid sequence consisting of amino acids 21 to 1039 of SEQ ID NO:2, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual, and a pharmaceutically acceptable adjuvant.
8. The isolated polypeptide of claim 1 , wherein the individual is a human, a mouse or a rat.
9. The vaccine composition of claim 5 , wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant, Freund's incomplete adjuvant, AlK(SO 4 ) 2 , AlNa(SO 4 ) 2 , AlNH 4 (SO 4 ) 2 , silica, kaolin, carbon polynucleotides, QuilA and Alhydrogel.
10. The isolated polypeptide of claim 1 , said polypeptide having at least a 99% identity to SEQ ID NO:2.
11. The vaccine composition of claim 5 , said polypeptide having at least a 99% identity to SEQ ID NO:2.
12. An isolated polypeptide comprising at least 95% sequence identity to amino acids 521 to 1039 of SEQ ID NO:2, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual.
13. An isolated polypeptide comprising at least 95% sequence identity to amino acids 800 to 1039 of SEQ ID NO:2, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual.
14. An isolated polypeptide comprising at least 95% sequence identity to amino acids 21 to 800 of SEQ ID NO:2, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual.
15. An isolated polypeptide comprising at least 95% sequence identity to amino acids 472 to 1039 of SEQ ID NO:2, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual.
16. A vaccine composition comprising a polypeptide having at least 95% sequence identity to amino acids 521 to 1039 of SEQ ID NO:2, and a pharmaceutically acceptable carrier, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual.
17. A vaccine composition comprising a polypeptide having at least 95% sequence identity to amino acids 800 to 1039 of SEQ ID NO:2, and a pharmaceutically acceptable carrier, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual.
18. A vaccine composition comprising a polypeptide having at least 95% sequence identity to amino acids 21 to 800 of SEQ ID NO:2, and a pharmaceutically acceptable carrier, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual.
19. A vaccine composition comprising a polypeptide having at least 95% sequence identity to amino acids 472 to 1039 of SEQ ID NO:2, and a pharmaceutically acceptable carrier, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual.